Investor Alert

Market Pulse Archives

Oct. 22, 2021, 7:20 a.m. EDT

23andMe buys telemedicine specialist Lemonaid Health

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    23andMe Holding Co. (ME)

or Cancel Already have a watchlist? Log In

By Steve Gelsi


23andMe Holding Co. /zigman2/quotes/222659849/composite ME +3.72% said Friday it agreed to pay $400 million for Lemonaid Health Inc., the on-demand platform for accessing medical care and pharmacy services, in a bid to add telemedicine and prescription drug delivery services. The purchase price includes 25% cash and 75% in shares of 23andMe Class A common stock. The company expects to close the deal by the end of the year. 23andMe CEO Anne Wojcicki said the company will combine its business of providing genetic profiles of consumers with giving patients and healthcare providers better information about health risks and treatments."Lemonaid Health's focus on the patient and its philosophy of delivering individualized care fits perfectly with our mission of empowering people to take control of their health," Wojcicki said. Shares of 23andMe are down 9.6% so far in 2021.

US : U.S.: Nasdaq
$ 2.51
+0.09 +3.72%
Volume: 1.59M
Jan. 27, 2023 4:00p
P/E Ratio
Dividend Yield
Market Cap
$1.14 billion
Rev. per Employee

Get news alerts on 23andMe Holding Co. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.